GEN inCode

GEN inCode

Safeguarding your future health with predictive genetics

2019
First invested

GEN inCode products combine genetic and clinical data to risk assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. GEN inCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. the molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset and clinical information to determine the most effective treatment pathway (precision medicine).

Meet the team

Related articles

Exonar builds momentum to enable enterprises to tackle data deluge - article

Exonar, the world leading data indexing and discovery platform, has today announced that it has secured furthe...

How to survive and thrive in 2021 as a VC firm according to Downing Ventures - article

In 2021, it has never been more important for venture capital firms to be able to differentiate.

Why We Invested In - Ayar Labs

We believe Ayar Labs can address many of the challenges of improving performance while also reducing energy co...